• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Carte­sian tees up Phase 3 mR­NA CAR-T study in myas­the­nia gravis

6 months ago
R&D

BMS inks deal with AI Pro­teins; Terns’ ear­ly-stage leukemia da­ta

6 months ago
News Briefing

Roivant says long-shot drug for a rare lung dis­ease failed its Phase 2 study

6 months ago
R&D

Af­ter deal about-face and a spin­out, Maze as­sem­bles $115M Se­ries D

6 months ago
Financing
Startups

Take­da to pay $200M for rights to ane­mia drug from Keros

6 months ago
Deals
Pharma

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

6 months ago
Startups
Deals

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

6 months ago
Financing
R&D

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

6 months ago
Deals
Pharma

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

6 months ago
R&D

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

6 months ago
FDA+

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing   

6 months ago
China
Manufacturing

J&J looks to ex­pand Trem­fya in two pe­di­atric in­di­ca­tions

6 months ago
Pharma
FDA+

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

6 months ago
People
FDA+

Bio­con lands FDA ap­proval for an­oth­er Ste­lara biosim­i­lar

6 months ago
Pharma
FDA+

Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al

6 months ago
Deals
R&D

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

6 months ago
R&D

Sen­ti Bio’s Phase 1 CAR-NK da­ta; Allink rais­es $42M

6 months ago
News Briefing

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

6 months ago
Financing
Manufacturing

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

6 months ago
Deals
Pharma

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

6 months ago
R&D

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

6 months ago
R&D

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

6 months ago
R&D
FDA+

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

6 months ago
Pharma
Cell/Gene Tx

Sat­suma's NDA fil­ing af­ter CMC woes; Hov­ione's Irish and US ex­pan­sion

6 months ago
Manufacturing
First page Previous page 70717273747576 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times